Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323614 | 0.94 | TAAR1 (0.36) | TAAR1SIGMAR1HTR2AHTR2CMEN1 | |
| SCHEMBL23323170 | 0.77 | CHRNB2 (0.44) | CHRM5CHRM1CHRM3 | |
| SCHEMBL23323175 | 0.76 | MEN1 (0.42) | TAAR1MEN1KMT2ACHRM5CHRM1 | |
| SCHEMBL30078318 | 0.76 | MEN1 (0.42) | TAAR1MEN1KMT2ACHRM5CHRM1 | |
| SCHEMBL23487422 | 0.76 | KDM4E (0.49) | TAAR1SIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL24774498 | 0.73 | HTR2A (0.33) | SIGMAR1HTR2AHTR2CSLC6A2KDM4E | |
| SCHEMBL28527431 | 0.73 | TAAR1 (0.43) | TAAR1HTR2AMEN1KMT2AKDM4E | |
| SCHEMBL28527428 | 0.73 | TAAR1 (0.43) | TAAR1HTR2AMEN1KMT2AKDM4E | |
| SCHEMBL28537464 | 0.73 | TAAR1 (0.43) | TAAR1HTR2AMEN1KMT2AKDM4E | |
| SCHEMBL20387676 | 0.73 | HTR2A (0.40) | HTR2AHTR2CMCHR1SLC6A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| WO-2021110102-A1 | METHODS OF CANCER TREATMENT USING BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021083135-A1 | Bcl-2 INHIBITORS | BEIGENE, LTD. (KY) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | TAAR1 4675/4885SIGMAR1 4800/4885HTR2A 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.